Literature DB >> 3162904

Pharmacokinetics of enoxacin and its penetration into bronchial secretions and lung tissue.

W J Wijnands1, T B Vree, A M Baars, C L van Herwaarden.   

Abstract

Pharmacokinetic data were obtained from four healthy volunteers after oral administration of a single 400 or 600 mg dose of enoxacin. Enoxacin was absorbed quickly and absorption was increased when enoxacin was ingested after a meal. Renal clearance of enoxacin and 4-oxo-enoxacin decreased after simultaneous administration of probenecid. In addition, pharmacokinetic parameters of enoxacin and its 4-oxo metabolite were determined for plasma and sputum from 19 patients treated with enoxacin, 400 or 600 mg bd, for a respiratory tract infection. The half-life of both enoxacin and 4-oxo-enoxacin was 5-6 h; during treatment with 400 and 600 mg bd, the plasma concentrations exceeded MIC values for most bacteria isolated in respiratory tract infections, including most Pseudomonas aeruginosa strains; Streptococcus pneumoniae was an exception. Diffusion from plasma to sputum was approximately 100%. Of an ingested dose, 60-65% was recovered in the urine in 24 h. In a third study, a single 600 mg dose of enoxacin was given to 15 patients undergoing thoracotomy. Subsequent lung tissue concentrations of enoxacin were significantly higher than plasma concentrations at the same time after ingestion.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3162904     DOI: 10.1093/jac/21.suppl_b.67

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  18 in total

1.  Concentrations of oral lomefloxacin in serum and bronchial mucosa.

Authors:  D R Baldwin; D Honeybourne; J M Andrews; J P Ashby; R Wise
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

2.  Competitive inhibition of renal tubular secretion of gemifloxacin by probenecid.

Authors:  Cornelia B Landersdorfer; Carl M J Kirkpatrick; Martina Kinzig; Jürgen B Bulitta; Ulrike Holzgrabe; George L Drusano; Fritz Sörgel
Journal:  Antimicrob Agents Chemother       Date:  2009-06-29       Impact factor: 5.191

3.  Transepithelial transport of the fluoroquinolone ciprofloxacin by human airway epithelial Calu-3 cells.

Authors:  M E Cavet; M West; N L Simmons
Journal:  Antimicrob Agents Chemother       Date:  1997-12       Impact factor: 5.191

4.  Pharmacokinetics of Intravenous Finafloxacin in Healthy Volunteers.

Authors:  Max Taubert; Joseph Chiesa; Mark Lückermann; Carsten Fischer; Axel Dalhoff; Uwe Fuhr
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

Review 5.  Enoxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  J M Henwood; J P Monk
Journal:  Drugs       Date:  1988-07       Impact factor: 9.546

Review 6.  Enoxacin: a reappraisal of its clinical efficacy in the treatment of genitourinary tract infections.

Authors:  S S Patel; C M Spencer
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

Review 7.  Ofloxacin clinical pharmacokinetics.

Authors:  K C Lamp; E M Bailey; M J Rybak
Journal:  Clin Pharmacokinet       Date:  1992-01       Impact factor: 6.447

8.  Competitive inhibition of renal tubular secretion of ciprofloxacin and metabolite by probenecid.

Authors:  Cornelia B Landersdorfer; Carl M J Kirkpatrick; Martina Kinzig; Jürgen B Bulitta; Ulrike Holzgrabe; Ulrich Jaehde; Andreas Reiter; Kurt G Naber; Michael Rodamer; Fritz Sörgel
Journal:  Br J Clin Pharmacol       Date:  2010-02       Impact factor: 4.335

9.  Concentrations of temafloxacin in serum and bronchial mucosa.

Authors:  D R Baldwin; L Wilkinson; J M Andrews; J P Ashby; R Wise; D Honeybourne
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-06       Impact factor: 3.267

Review 10.  Role of quinolones in the treatment of bronchopulmonary infections, particularly pneumococcal and community-acquired pneumonia.

Authors:  J P Thys; F Jacobs; B Byl
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-04       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.